Microbot Medical MBOT Proceeds from issuance of shares
Proceeds from issuance of shares at other companies
Other financials
Where this comes from
Reported directly by Microbot Medical in its filing.
Tagged under the XBRL concept us-gaap:ProceedsFromIssuanceOrSaleOfEquity.
The official record: Microbot Medical’s 10-Q, filed August 12, 2025, on SEC EDGAR. View the filing →
Ask your AI about Microbot Medical's proceeds from issuance of shares.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Microbot Medical's proceeds from issuance of shares?
- Microbot Medical (MBOT) reported proceeds from issuance of shares of $4.75M in Q2 2025.
- How has Microbot Medical's proceeds from issuance of shares changed year-over-year?
- Microbot Medical's proceeds from issuance of shares increased by 129.1% year-over-year, from $2.07M to $4.75M.
- What is the long-term trend for Microbot Medical's proceeds from issuance of shares?
- Over 2 years (2022 to 2024), Microbot Medical's proceeds from issuance of shares has grown at a 35.5% compound annual growth rate (CAGR), from $4.32M to $7.94M.
- What does proceeds from issuance of shares mean?
- Represents the total cash inflows received from the issuance of new common or preferred stock to investors. This metric is a critical indicator of the company's ability to raise external capital to fund growth, research, or operational deficits. It highlights the dilution impact on existing shareholders and the company's reliance on equity markets.